|
|
Article: Enzon, Pharmagene Developing PEGylated Cystic Fibrosis Drug.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Staff Writer
Potentially providing an enhanced therapy for cystic fibrosis patients, Enzon Pharmaceuticals Inc. agreed with Pharmagene plc to collaborate on the development of long-acting PGN0052, a synthetic version of human secretin.
Enzon, of Bridgewater, N.J., will use its PEGylation technology to engineer a molecule with optimized pharmacokinetic properties and an extended duration of action.
"This is just us putting the seeds down for our future pipeline," said Kenneth Zuerblis, Enzon's vice president of finance and chief financial officer.
Enzon will receive an initial fee upon signing the agreement and a milestone payment once ...